Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery

SIMPLE SUMMARY: Immune checkpoint inhibitors (ICIs) have been investigated in epithelial ovarian cancer in first-line and recurrent settings. When used as a single agent or in combination with chemotherapy, they have largely failed to improve patients’ outcome and thus, have not entered routine use...

Descripción completa

Detalles Bibliográficos
Autores principales: Colombo, Ilaria, Karakasis, Katherine, Suku, Sneha, Oza, Amit M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296292/
https://www.ncbi.nlm.nih.gov/pubmed/37370830
http://dx.doi.org/10.3390/cancers15123220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296292/
https://www.ncbi.nlm.nih.gov/pubmed/37370830
http://dx.doi.org/10.3390/cancers15123220

Ejemplares similares